NYSE MKT
NNVC

NanoViricides Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

NanoViricides Inc Stock Price

Vitals

Today's Low:
$1.27
Today's High:
$1.341
Open Price:
$1.28
52W Low:
$1.04
52W High:
$2.03
Prev. Close:
$1.3
Volume:
7490

Company Statistics

Market Cap.:
$15.21 million
Book Value:
1.562
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-20.18%
Return on Equity TTM:
-31.63%

Company Profile

NanoViricides Inc had its IPO on 2005-10-26 under the ticker symbol NNVC.

The company operates in the Healthcare sector and Biotechnology industry. NanoViricides Inc has a staff strength of 17 employees.

Stock update

Shares of NanoViricides Inc opened at $1.28 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.27 - $1.34, and closed at $1.31.

This is a +0.77% increase from the previous day's closing price.

A total volume of 7,490 shares were traded at the close of the day’s session.

In the last one week, shares of NanoViricides Inc have slipped by -9.66%.

NanoViricides Inc's Key Ratios

NanoViricides Inc has a market cap of $15.21 million, indicating a price to book ratio of 0.7025 and a price to sales ratio of 0.

In the last 12-months NanoViricides Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-6313275. The EBITDA ratio measures NanoViricides Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, NanoViricides Inc’s operating margin was 0% while its return on assets stood at -20.18% with a return of equity of -31.63%.

In Q1, NanoViricides Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

NanoViricides Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-0.58 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into NanoViricides Inc’s profitability.

NanoViricides Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.3563. Its price to sales ratio in the trailing 12-months stood at 0.

NanoViricides Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$18.58 million
Total Liabilities
$348744.00
Operating Cash Flow
$0
Capital Expenditure
$59301
Dividend Payout Ratio
0%

NanoViricides Inc ended 2024 with $18.58 million in total assets and $0 in total liabilities. Its intangible assets were valued at $18.58 million while shareholder equity stood at $18.23 million.

NanoViricides Inc ended 2024 with $0 in deferred long-term liabilities, $348744.00 in other current liabilities, 11666.00 in common stock, $-127510756.00 in retained earnings and $0 in goodwill. Its cash balance stood at $9.65 million and cash and short-term investments were $9.65 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

NanoViricides Inc’s total current assets stands at $9.93 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $62695.00 and inventory worth $0.

In 2024, NanoViricides Inc's operating cash flow was $0 while its capital expenditure stood at $59301.

Comparatively, NanoViricides Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$1.31
52-Week High
$2.03
52-Week Low
$1.04
Analyst Target Price
$5.25

NanoViricides Inc stock is currently trading at $1.31 per share. It touched a 52-week high of $2.03 and a 52-week low of $2.03. Analysts tracking the stock have a 12-month average target price of $5.25.

Its 50-day moving average was $1.44 and 200-day moving average was $1.34 The short ratio stood at 11.27 indicating a short percent outstanding of 0%.

Around 437.9% of the company’s stock are held by insiders while 1074% are held by institutions.

Frequently Asked Questions About NanoViricides Inc

The stock symbol (also called stock or share ticker) of NanoViricides Inc is NNVC

The IPO of NanoViricides Inc took place on 2005-10-26

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$6.72
0.04
+0.6%
$13.44
0.38
+2.91%
Komatsu Ltd (KMTUY)
$29.7
0.5
+1.71%
$17.31
0.57
+3.41%
$17.21
0.08
+0.47%
$47.57
0.27
+0.57%
$117.6
1.05
+0.9%
$43.01
-1.69
-3.78%
$263.25
-17.6
-6.27%
$10.86
0.01
+0.09%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Monkeypox Treatment for Monkeypox virus; Adenovirus 71 Treatment for severe pediatric hepatitis caused by Adenovirus 71 or related viruses; and HerpeCide Program Expansion Drug project that develops broad-spectrum nanoviricide drugs against different herpes viruses for different indications. The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. The company was founded in 2005 and is based in Shelton, Connecticut.

Address

1 Controls Drive, Shelton, CT, United States, 06484